Azitra (AZTR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 May, 2026Executive summary
The annual meeting originally scheduled for June 4, 2026, will be convened and immediately adjourned due to an administrative delay in mailing proxy materials, with reconvening set for June 15, 2026, in virtual format.
The record date for voting remains April 24, 2026, and no changes have been made to the proposals to be voted on.
Stockholders who have already voted do not need to take further action unless they wish to change their vote.
Voting can be completed by mail, internet, or telephone, with instructions provided in the proxy statement.
Forward-looking statements regarding the meeting and proposals are subject to risks and uncertainties as outlined in company filings.
Voting matters and shareholder proposals
All proposals to be voted on at the reconvened meeting remain unchanged from those previously disclosed.
Stockholders are encouraged to vote by June 15, 2026, at 10:59 a.m. Eastern Time, or during the live webcast.
Board of directors and corporate governance
The Board of Directors and management request that eligible stockholders consider and vote their proxies as soon as possible.
Latest events from Azitra
- Precision dermatology pipeline advances with engineered bacteria and key 2026 milestones ahead.AZTR
Corporate presentation26 May 2026 - Advancing engineered skin microbiome therapies for rare and common dermatological conditions.AZTR
Corporate presentation26 May 2026 - Net loss narrowed in Q2 2024 as $10M financing supports advancing clinical pipeline.AZTR
Q2 202426 May 2026 - Net loss narrowed to $1.0 million, but cash may not last twelve months.AZTR
Q3 202426 May 2026 - Narrowed net loss to $9M, advanced clinical trials, and raised $15M in new funding.AZTR
Q4 202426 May 2026 - Net loss rose 5% to $3.1 million in Q1 2025; more funding is needed for clinical progress.AZTR
Q1 202526 May 2026 - Net loss widened to $2.9M, cash remains low, and future depends on new funding and clinical milestones.AZTR
Q2 202526 May 2026 - Net loss rose to $2.8M in Q3 2025; cash at $1.4M, raising going concern doubts.AZTR
Q3 202526 May 2026 - Net loss increased to $11.0 million as clinical programs advanced and cash reserves declined.AZTR
Q4 202526 May 2026